Morgan Stanley raised target for Sandoz stock from CHF 55 to CHF 60

Published on 10/12/2026 at 09:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sandoz sales grew 5.00 percent in the first half of 2026. Sandoz stock costs EUR 75.16 on October 12, 2026 at a CHF 30.4 billion value.

Key points in brief

Morgan Stanley raised its Sandoz price target from CHF 55 to CHF 60 on October 6, 2026, while retaining an Underweight rating.
First-half net sales increased 5.00 percent at constant currencies to USD 5.8 billion, with biosimilars growing 20.00 percent.
Sandoz stock was trading at EUR 75.16 at Lang & Schwarz on October 12, 2026 at 9:15 a.m. CEST; market capitalization was CHF 30.4 billion.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz (CH1243598427) was trading at EUR 75.16 at Lang & Schwarz on October 12, 2026 at 9:15 a.m. CEST. The latest analyst move came on October 6, 2026, when Morgan Stanley analyst Thibault Boutherin raised the price target from CHF 55 to CHF 60 while keeping an Underweight rating, as Markets Insider reported.

Morgan Stanley set a CHF 60 target

The CHF 60 target remains below the EUR reference price only as a cross-currency comparison is not valid, so the analyst call is best read as a view on Sandoz's Swiss-listed shares rather than as a direct valuation gap to the Lang & Schwarz quote. Morgan Stanley's Underweight rating also provides a counterweight to the company's operating progress.

First-half sales reached USD 5.8 billion

In the first half of 2026, net sales increased 5.00 percent at constant currencies to USD 5.8 billion, according to Yahoo Finance. Biosimilar sales grew 20.00 percent in the same period, while quarter-two growth reached 7.00 percent, giving the portfolio a clear role in the sales mix.

What does the margin say?

Core EBITDA increased 15.00 percent in the first half of 2026, and the core EBITDA margin expanded 90 basis points to 20.90 percent, according to Yahoo Finance. Management also said pricing was expected to decline by a mid-single-digit percentage in 2026, while biosimilar volume growth and product mix supported profitability.

Three dated milestones shaped the year

On August 5, 2026, Sandoz reported first-half net sales growth of 5.00 percent at constant currencies. On August 5, 2026, management said the biosimilar pipeline contained 36 assets and that biosimilars represented 33.00 percent of first-half net sales, according to Yahoo Finance. On October 6, 2026, Morgan Stanley raised its target to CHF 60 from CHF 55, keeping the Underweight rating.

EUR 75.16 at Lang & Schwarz

Sandoz was trading at EUR 75.16 at Lang & Schwarz on October 12, 2026 at 9:15 a.m. CEST. The company had a market capitalization of CHF 30.4 billion as of October 12, 2026, while its primary listing is on SIX in Switzerland.

The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.